Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6121 to 6135 of 7681 results

  1. What measures would make up an effective, standardised approach to evaluation of condom distribution schemes?: How can we develop a standardised framework to evaluate condom schemes and what would be included in that evaluation?

    Recommendation ID NG68/1 Question What measures would make up an effective, standardised approach to evaluation of condom distribution

  2. What methods can improve the identification of women at high risk of postpartum psychosis and reduce this risk?

    Recommendation ID CG192/1 Question What methods can improve the identification of women at high risk of postpartum psychosis and reduce

  3. What is the most clinical and cost-effective strategy, as identified by a consensus survey, for the perioperative management of anticoagulation treatment in people taking a vitamin K antagonist with a target international normalised ratio (INR) of more than 3 who need bridging therapy?

    Recommendation ID NG180/3 Question What is the most clinical and cost-effective strategy, as identified by a consensus survey, for the

  4. For how long should a person who has received emergency treatment for anaphylaxis be observed?

    Recommendation ID CG134/3 Question For how long should a person who has received emergency treatment for anaphylaxis be observed?

  5. Aside from mast cell tryptase, which other chemical inflammatory mediators offer potential as indicators of anaphylaxis?

    Recommendation ID CG134/1 Question Aside from mast cell tryptase, which other chemical inflammatory mediators offer potential as indicators

  6. What are the optimal management strategies for primary hyperparathyroidism during pregnancy?

    Recommendation ID NG132/4 Question What are the optimal management strategies for primary hyperparathyroidism during pregnancy?

  7. Measuring improvements in care home residents' oral health:- How can interventions to improve and maintain oral health and wellbeing, or to prevent dental disease, be measured using a patient-centred approach that can also be used to judge cost effectiveness?

    Recommendation ID NG48/3 Question Measuring improvements in care home residents' oral health:- How can interventions to improve and maintain

  8. Premature ovarian insufficiency:- What are the main clinical manifestations of premature ovarian insufficiency and the short- and long-term impact of the most common therapeutic interventions?

    Recommendation ID NG23/5 Question Premature ovarian insufficiency:- What are the main clinical manifestations of premature ovarian insufficiency

  9. Effects of HRT on venous thromboembolism risk:- How does the preparation of HRT affect the risk of venous thromboembolism (VTE)?

    Recommendation ID NG23/3 Question Effects of HRT on venous thromboembolism risk:- How does the preparation of HRT affect the risk of venous

  10. Effects of HRT on breast cancer risk:- What is the difference in the risk of breast cancer in menopausal women on HRT with progesterone, progestogen or selective oestrogen receptor modulators?

    Recommendation ID NG23/2 Question Effects of HRT on breast cancer risk:- What is the difference in the risk of breast cancer in menopausal

  11. Women with breast cancer:- What is the safety and effectiveness of alternatives to systemic HRT as treatments for menopausal symptoms in women who have had treatment for breast cancer?

    Recommendation ID NG23/1 Question Women with breast cancer:- What is the safety and effectiveness of alternatives to systemic HRT as treatments

  12. AI technologies recommended for use in detecting fractures

    Draft guidance issued for consultation recommends the use of 4 AI technologies to help professionals detect fractures in urgent care settings.

  13. New Alzheimer's treatment donanemab does not currently demonstrate value for the NHS says NICE

    More evidence is needed on the clinical and cost-effectiveness of donanemab, a new treatment for mild Alzheimer’s disease.